Clinical Analysis: 44-Year-Old with Recurrent Pelvic Mass After Ovarian Cystectomy

Summary of the Clinical Scenario

Step 1: Differential Diagnosis of the Current Pelvic Mass

1. Recurrent Endometrioma (left, or bilateral)

• Conservative surgery carries high recurrence rates: 2-20% per year, with cumulative rates of 4-25% at 2 years and up to 40% at 5 years (Berek & Novak's Gynecology, p. 684)
• Risk factors that apply here: previous surgery (the strongest predictor), young age at diagnosis, and left-sided involvement (left-sided disease has a higher recurrence risk than right-sided disease)
• She also had an endometrioma on the left specifically, and the literature notes left-sided endometriosis has a higher recurrence probability

2. Recurrent / Residual Serous Tumor - Benign or Borderline

• 5-10% of serous tumors have borderline malignant potential, and 20-25% are malignant - Berek & Novak's Gynecology, p. 454
• A borderline tumor cannot be distinguished from benign on gross examination alone - frozen section is required
• Borderline serous tumors may recur after many years; 5-year survival is not synonymous with cure for borderline tumors - Robbins & Cotran, p. 943
• At 44 years of age, the risk of epithelial tumors increases, making this possibility more significant than it would have been in a younger woman

3. De Novo Ovarian Neoplasm (New Primary Tumor)

• New endometrioma on the right (her previously operated side)
• New epithelial ovarian neoplasm
• Endometriosis can transform into endometrioid carcinoma or clear cell carcinoma - this is a well-recognized though uncommon malignant transformation of endometriosis

4. Malignant Transformation / Ovarian Cancer

• Must be ruled out at this age with a new pelvic mass
• The WHO classification places serous cystadenoma in the same lineage as serous cystadenocarcinoma (Type I pathway: cystadenoma → borderline tumor → low-grade serous carcinoma)

Fig. 22.29 - Pathogenesis of ovarian epithelial tumors (Robbins, Cotran & Kumar Pathologic Basis of Disease)

Step 2: Histological Spectrum of Serous Tumors (Key Point for This Patient)

Fig. 22.32 - Microscopic appearances of serous tumors (Robbins, Cotran & Kumar Pathologic Basis of Disease)

Step 3: Workup (Recommended Approach)

History & Examination

• Character of pain: cyclical (suggests endometrioma) vs. constant (malignancy concern)
• Menstrual changes, dysmenorrhea, dyspareunia
• Weight loss, anorexia (red flag symptoms)
• Family history of BRCA1/2, breast/ovarian cancer, Lynch syndrome

Investigations

Ultrasound Features Concerning for Malignancy (from Berek & Novak's):

• Multiloculations
• Cyst size > 10 cm
• Solid components or papillary projections
• Thick septations
• Irregular walls/nodularity
• Ascites
• Bilateral masses
• Abnormal color Doppler flow (low-resistance pattern)

Step 4: Management Algorithm

New pelvic mass post-cystectomy
        ↓
Clinical + Imaging (TVS + MRI) + Tumor markers
        ↓
    ┌─────────────────────────────┐
    │                             │
Likely benign features     Suspicious/malignant features
(simple cyst, CA-125 low)  (solid components, ascites,
                            elevated markers, large size)
    ↓                             ↓
Expectant management         Prompt surgical evaluation
(if asymptomatic, <10cm)    by gynecologic oncologist
    ↓
Symptomatic / growing
    ↓
Laparoscopic cystectomy
(fertility-sparing preferred)
with INTRAOPERATIVE FROZEN SECTION
    ↓
    ┌──────────────────────────────────────┐
    │                                      │
Benign                              Borderline/Malignant
    ↓                                      ↓
Cystectomy adequate;          Staging laparotomy / full
postop OCP/GnRH agonist       surgical staging (TAH+BSO
to prevent endometriosis      + omentectomy + lymphadenectomy)
recurrence

Step 5: Specific Concerns in This Patient

Regarding the Right Side (Previous Serous Cystadenoma)

• Any new mass on the right must rule out borderline or malignant transformation - a frozen section at the time of any re-operation is non-negotiable
• Serous borderline tumors can recur years after initial surgery; 5-year survival ≠ cure
• Low-grade serous carcinomas (Type I pathway) carry KRAS/BRAF mutations and progress slowly

Regarding the Left Side (Previous Endometrioma)

• High risk of recurrence: overall endometriosis recurrence up to 40% at 5 years
• Prevention of recurrence: After conservative surgery, OCP use significantly reduces endometrioma recurrence. One study showed recurrence in only 10% of OCP users vs. 40% of non-users (OR 0.16; 95% CI 0.04-0.65) - Berek & Novak's, p. 685
• Medical treatment of recurrence is an option before repeat surgery in symptomatic endometriosis (GnRH agonists, dienogest, OCP)
• Endometriosis can undergo malignant transformation to endometrioid or clear cell carcinoma - this should be kept in mind at 44 years

Age Consideration (44 years)

• She is approaching perimenopause; if she has completed her family, a discussion about definitive surgery (bilateral salpingo-oophorectomy) is appropriate, especially if a second laparoscopic cystectomy is being planned
• Repeat conservative surgery for endometriosis is associated with diminishing returns and increasing adhesion risk

Prevention of Recurrence (Post-Operative)

• Women should seek conception promptly if desired, OR
• Use oral contraceptive pills (cyclic or continuous) until pregnancy is desired
• Postoperative long-term OCP (24 months) significantly reduces recurrence vs. no treatment
• GnRH agonists with add-back therapy for patients who cannot tolerate OCP

Bottom Line

1. Transvaginal ultrasound + MRI pelvis as the primary imaging
2. CA-125, HE4, ROMA score for malignancy risk stratification
3. Surgical intervention is indicated given she is symptomatic (pain) with a palpable mass
4. Laparoscopic re-exploration with frozen section - this is the standard approach
5. The most important concern at this age is ruling out a serous borderline tumor or low-grade serous carcinoma from the right ovary, and endometrioma recurrence or malignant transformation from the left
6. If repeat cystectomy is chosen, discuss definitive surgery as an alternative given her age and bilateral disease history
7. Postoperative suppressive therapy (OCP or GnRH agonist) regardless of outcome to prevent further endometriosis recurrence